Combination of anti-CD20 antibody with Bcl-2 inhibitor and MDM2 inhibitor

摘要

The present invention relates to a combination therapy of an anti-CD20 antibody with a Bcl-2 inhibitor and an MDM2 inhibitor for the treatment of cancer, in particular a combination of a Type I anti-CD20 antibody or afucosylated humanized B-Ly1 antibody and a Bcl-2 inhibitor and an MDM2 inhibitor Lt; RTI ID = 0.0 CD20 / RTI Preferably, the anti-CD20 antibody is ovine to thymid. Preferably, the Bcl-2 inhibitor is Venetoclase. Preferably, the MDM2 inhibitor is RG7388.